Bibliografía del artículo
1. Crane GE. Iproniazid (marsilid) phosphate, a therapeutic agent for mental disorders and debilitating diseases. Psychiatr Res Rep Am Psychiatr Assoc 135:142-52, 1957.
2. Schildkraut JJ. The catecholamine hypothesis of affective disorders: a review of supporting evidence. Am J Psychiatry 122:509-22, 1965.
3. Praag HV. Depresion, suicide and serotonin metabolism in the brain. In: Post RM, Ballenger JC, editors. Neurobiology of mood disorders. Baltimore: Williams and Wilkins pp. 601-618, 1964.
4. Ballesteros J, Callado LF, Gutiérrez M. An independent meta-analysis using summary data for clinical response, remission, and discontinuation for any reason from the 6 pivotal phase III randomized clinical trials of duloxetine in major depressive disorder. J Clin Psychopharmacol 27:219-21, 2007.
5. Heninger GR, Delgado PL, Charney DS. The revised monoamine theory of depression: a modulatory role for monoamines, based on new findings from monoamine depletion experiments in humans. Pharmacopsychiatry 29:2-11, 1996.
6. Delgado PL, Charney DS, Price LH et al. Serotonin function and the mechanism of antidepressant action. Reversal of antidepressant-induced remission by rapid depletion of plasma tryptophan. Arch Gen Psychiatry 47:411-8, 1990.
7. Delgado PL, Miller HL, Salomon RM et al. Tryptophan-depletion challenge in depressed patients treated with desipramine or fluoxetine: implications for the role of serotonin in the mechanism of antidepressant action. Biol Psychiatry 46:212-20, 1999.
8. Miller HL, Delgado PL, Salomon RM et al. Clinical and biochemical effects of catecholamine depletion on antidepressant-induced remission of depression. Arch Gen Psychiatry 53:117-28, 1996.
9. Delgado PL, Miller HL, Salomon RM et al. Monoamines and the mechanism of antidepressant action: effects of catecholamine depletion on mood of patients treated with antidepressants. Psychopharmacol Bull 29:389-96, 1993.
10. Young SN, Smith SE, Pihl RO et al. Tryptophan depletion causes a rapid lowering of mood in normal males. Psychopharmacology (Berl) 87:173-7, 1985.
11. Smith SE, Pihl RO, Young SN et al. A test of possible cognitive and environmental influences on the mood lowering effect of tryptophan depletion in normal males. Psychopharmacology (Berl) 91:451-7, 1987.
12. Smith KA, Fairburn CG, Cowen PJ. Relapse of depression after rapid depletion of tryptophan. Lancet 349:915-9, 1997.
13. Moreno FA, Gelenberg AJ, Heninger GR et al. Tryptophan depletion and depressive vulnerability. Biol Psychiatry 46:498-505, 1999.
14. Benkelfat C, Ellenbogen MA, Dean P et al. Mood-lowering effect of tryptophan depletion. Enhanced susceptibility in young men at genetic risk for major affective disorders. Arch Gen Psychiatry 51:687-97, 1994.
15. Blier P, De Montigny C. Current advances and trends in the treatment of depression. Trends Pharmacol Sci 15:220-6, 1994.
16. Artigas F, Romero L, De Montigny C et al. Acceleration of the effect of selected antidepressant drugs in major depression by 5-HT1A antagonists. Trends Neurosci 19:378-83, 1996.
17. Mateo Y, Fernández Pastor B, Meana JJ. Acute and chronic effects of desipramine and clorgyline on alpha(2)-adrenoceptors regulating noradrenergic transmission in the rat brain: a dual-probe microdialysis study. Br J Pharmacol 133:1362-70, 2001.
18. Brunello N, Mendlewicz J, Kasper S et al. The role of noradrenaline and selective noradrenaline reuptake inhibition in depression. Eur Neuropsychopharmacol 12:461-75, 2002.
19. Hashimoto K, Shimizu E, Iyo M. Critical role of brain-derived neurotrophic factor in mood disorders. Brain Res Brain Res Rev 45:104-14, 2004.
20. Duman RS, Monteggia LM. A neurotrophic model for stress-related mood disorders. Biological Psychiatry 59:1116-1127, 2006.
21. Chen B, Dowlatshahi D, MacQueen GM et al. Increased hippocampal bdnf immunoreactivity in subjects treated with antidepressant medication. Biological Psychiatry 50:260-265, 2001.
22. Karege F, Vaudan G, Schwald M et al. Neurotrophin levels in postmortem brains of suicide victims and the effects of antemortem diagnosis and psychotropic drugs. Brain Res Mol Brain Res 136:29-37, 2005.
23. Piccinni A, Marazziti D, Catena M et al. Plasma and serum brain-derived neurotrophic factor (BDNF) in depressed patients during 1 year of antidepressant treatments. Journal of Affective Disorders Vol in press, corrected proof, 2007.
24. Castren E, Voikar V, Rantamaki T. Role of neurotrophic factors in depression. Curr Opin Pharmacol 7:18-21, 2007.
25. Tsankova NM, Berton O, Renthal W et al. Sustained hippocampal chromatin regulation in a mouse model of depression and antidepressant action. Nat Neurosci 9:519-25, 2006.
26. Berton O, Nestler EJ. New approaches to antidepressant drug discovery: beyond monoamines. Nat Rev Neurosci 7:137-51, 2006.
27. Sheline YI, Gado MH, Kraemer HC. Untreated depression and hippocampal volume loss. Am J Psychiatry 160:1516-8, 2003.
28. Bremner JD, Vythilingam M, Vermetten E et al. Effects of glucocorticoids on declarative memory function in major depression. Biol Psychiatry 55:811-5, 2004.
29. Drevets WC. Neuroimaging abnormalities in the amygdala in mood disorders. Ann NY Acad Sci 985:420-44, 2003.
30. Rajkowska G. Postmortem studies in mood disorders indicate altered numbers of neurons and glial cells. Biol Psychiatry 48:766-77, 2000.
31. Rubin RT, Phillips JJ, Sadow TF et al. Adrenal gland volume in major depression. Increase during the depressive episode and decrease with successful treatment. Arch Gen Psychiatry 52:213-8, 1995.
32. Fries E, Hesse J, Hellhammer J et al. A new view on hypocortisolism. Psychoneuroendocrinology 30:1010-6, 2005.
33. Raadsheer FC, Hoogendijk WJ, Stam FC et al. Increased numbers of corticotropin-releasing hormone expressing neurons in the hypothalamic paraventricular nucleus of depressed patients. Neuroendocrinology 60:436-44, 1994.
34. Arborelius L, Owens MJ, Plotsky PM et al. The role of corticotropin-releasing factor in depression and anxiety disorders. J Endocrinol 160:1-12, 1999.
35. Lopez JF, Chalmers DT, Little KY et al. A.E. Bennett Research Award. Regulation of serotonin1A, glucocorticoid, and mineralocorticoid receptor in rat and human hippocampus: implications for the neurobiology of depression. Biol Psychiatry 43:547-73, 1998.